From USFDA
Zydus Cadila has received the final approval from the USFDA to market Topiramate Extended-Release Capsules in the strengths of 25 mg, 50 mg and 100 mg. The drug is indicated for the treatment of seizures and migraine headaches. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
